RT Journal Article
SR Electronic
T1 SARS-CoV-2 third vaccine immune response in MS patients treated with ocrelizumab
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.01.26.22269876
DO 10.1101/2022.01.26.22269876
A1 Brill, Livnat
A1 Raposo, Catarina
A1 Rechtman, Ariel
A1 Zveik, Omri
A1 Levin, Netta
A1 Oiknine-Djian, Esther
A1 Wolf, Dana G.
A1 Vaknin-Dembinsky, Adi
YR 2022
UL http://medrxiv.org/content/early/2022/01/28/2022.01.26.22269876.abstract
AB The introduction of a third dose vaccination along with new variants of concerns raises questions regarding serology and T-cell responses in patients with MS (pwMS) treated with B-cell depletion who develop attenuated humoral response to vaccines. The aim of this study is to longitudinally evaluate humoral and cellular response to SARS-CoV-2 mRNA vaccine in ocrelizumab-treated pwMS before and following third vaccine dose. Following the third vaccine dose, patients who are low or non-responders following initial vaccination did not increase antibody titers. In HCs and ocrelizumab-treated pwMS, cellular response decreased 6 months following initial vaccination and increased significantly after the third booster.Competing Interest StatementThis work was partially supported by F. Hoffmann-La Roche Ltd, Basel, SwitzerlandFunding StatementThis work was partially supported by F. Hoffmann-La Roche Ltd, Basel, SwitzerlandAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of Hadassah medical center gave ethical approval for this work (975-20 HMO)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors